SOPHiA GENETICS (SOPH) CLO details options and RSU stake

Rhea-AI Filing Summary

SOPHiA GENETICS SA filed an initial ownership report for Chief Legal Officer Daan Van Well, outlining his equity position in the company. He directly holds 261,922 ordinary shares, which includes 97,620 ordinary shares issuable upon settlement of four restricted stock unit grants that vest over time based on continued service. He also holds several option awards to buy ordinary shares, with exercise prices ranging from $3.29 to $18.00 per share and expiration dates between 2029 and 2035, providing long-term equity exposure but reflecting holdings rather than new market transactions.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Van Well Daan

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	261,922(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(2)	05/02/2029	Ordinary Shares	2,500	$3.93	D
Share Option (Right to Buy)	(2)	11/26/2029	Ordinary Shares	3,000	$4.01	D
Share Option (Right to Buy)	(2)	06/25/2030	Ordinary Shares	15,000	$4.21	D
Share Option (Right to Buy)	(2)	01/28/2031	Ordinary Shares	39,000	$6.31	D
Share Option (Right to Buy)	(2)	07/22/2031	Ordinary Shares	84,906	$18	D
Share Option (Right to Buy)	(3)	04/03/2033	Ordinary Shares	148,699	$4.72	D
Share Option (Right to Buy)	(4)	04/02/2034	Ordinary Shares	217,226	$4.96	D
Share Option (Right to Buy)	(5)	04/02/2035	Ordinary Shares	161,932	$3.29	D

Explanation of Responses:

1. Includes 97,620 ordinary shares issuable upon settlement of four restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 3,042 ordinary shares from a May 18, 2022 grant vesting in equal monthly installments through May 18, 2026; (ii) 30,267 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 27,660 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (iv) 36,651 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.

2. The share options are fully vested and exercisable.

3. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.

4. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.

5. The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.

Remarks:

Exhibit list - Exhibit 24 - Power of Attorney

	/s/ Elimara Brunetto as Attorney-in-Fact for Daan van Well	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the SOPHiA GENETICS (SOPH) Form 3 filing show for Daan Van Well?

The Form 3 shows Chief Legal Officer Daan Van Well’s existing equity position, including direct ownership of 261,922 ordinary shares and multiple option grants and RSUs that vest over several years, giving him long-term exposure to SOPHiA GENETICS’ share performance.

How many SOPHiA GENETICS ordinary shares does Daan Van Well hold directly?

Daan Van Well directly holds 261,922 ordinary shares of SOPHiA GENETICS. This figure includes shares already issued plus 97,620 ordinary shares that may be issued in the future upon settlement of time-based restricted stock unit awards, subject to his continued service.

What restricted stock units are reported for SOPHiA GENETICS CLO Daan Van Well?

The filing reports 97,620 ordinary shares issuable upon settlement of four RSU grants. These RSUs vest in monthly or quarterly installments from 2022 through 2028, with one grant vesting 50% on April 2, 2026, all conditioned on continued service with SOPHiA GENETICS.

What stock options does Daan Van Well hold in SOPHiA GENETICS?

Daan Van Well holds several share options to buy SOPHiA GENETICS ordinary shares, with exercise prices between $3.29 and $18.00 per share. These options cover different blocks of underlying shares and expire between 2029 and 2035, indicating long-dated equity incentives.

Are any of Daan Van Well’s SOPHiA GENETICS options fully vested and exercisable?

Yes. A footnote states that certain share options are fully vested and exercisable, meaning he can already purchase the underlying ordinary shares at the specified exercise prices, while other option grants continue to vest in installments over future years, subject to continued employment.

Does the SOPHiA GENETICS Form 3 indicate recent buying or selling by Daan Van Well?

The Form 3 primarily lists holdings of ordinary shares, RSUs, and options for Daan Van Well, rather than new open-market purchases or sales. It establishes his baseline ownership position as Chief Legal Officer, which future Forms 4 would update if transactions occur.